Show simple item record

dc.contributor.authorSherer, Christopher
dc.contributor.authorTolaymat, Ibrahim
dc.contributor.authorRowther, Farzana
dc.contributor.authorWarr, Tracy
dc.contributor.authorSnape, Timothy J
dc.date.accessioned2017-05-10T14:21:57Z
dc.date.available2017-05-10T14:21:57Z
dc.date.issued2017-02-17
dc.identifier.citationSherer C., Tolaymat I., Rowther F., Warr T., Snape TJ. (2017) 'Preliminary SAR on indole-3-carbinol and related fragments reveals a novel anticancer lead compound against resistant glioblastoma cells', Bioorganic & Medicinal Chemistry Letters, 27 (7) pp. 1561-1565
dc.identifier.issn0960-894X
dc.identifier.pmid28256372
dc.identifier.doi10.1016/j.bmcl.2017.02.033
dc.identifier.urihttp://hdl.handle.net/2436/620470
dc.description.abstractThe prognosis for glioblastoma patients is, at best, poor, with the median time of survival after diagnosis measured in months. As such, there is much need for the rapid development of potent and novel treatments. Herein, we report our preliminary findings on the SAR of a series of indole-3-carbinol and related fragments and reveal a potent lead with low micromolar activity against a particularly resistant glioblastoma cell culture, providing a new platform for future development of a new therapy in this area.
dc.language.isoen
dc.publisherElsevier
dc.subjectindole-3-carbinol
dc.subject3,3’-diindoloylmethane
dc.subjectglioblastoma
dc.subjectCancer
dc.subjectSAR
dc.titlePreliminary SAR on indole-3-carbinol and related fragments reveals a novel anticancer lead compound against resistant glioblastoma cells
dc.typeJournal article
dc.identifier.journalBioorganic & Medicinal Chemistry Letters
dc.date.accepted2017-02-15
rioxxterms.funderUniversity of Wolverhampton
rioxxterms.identifier.projectUOW100570TW
rioxxterms.versionAM
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
rioxxterms.licenseref.startdate2018-02-17
dc.source.volume27
dc.source.issue7
dc.source.beginpage1561
dc.source.endpage1565
refterms.dateFCD2018-10-19T09:28:38Z
refterms.versionFCDAM
refterms.dateFOA2018-02-17T00:00:00Z
html.description.abstractThe prognosis for glioblastoma patients is, at best, poor, with the median time of survival after diagnosis measured in months. As such, there is much need for the rapid development of potent and novel treatments. Herein, we report our preliminary findings on the SAR of a series of indole-3-carbinol and related fragments and reveal a potent lead with low micromolar activity against a particularly resistant glioblastoma cell culture, providing a new platform for future development of a new therapy in this area.


Files in this item

Thumbnail
Name:
Publisher version
Thumbnail
Name:
Snape - Paper MS - Final 2017.pdf
Size:
684.2Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc-nd/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/